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Suppressed autophagic response 
underlies augmentation of renal 
ischemia/reperfusion injury by type 
2 diabetes
Shingo Muratsubaki1, Atsushi Kuno1,2, Masaya Tanno1, Takayuki Miki1, Toshiyuki Yano1, 
Hirohito Sugawara1, Satoru Shibata1, Koki Abe1, Satoko Ishikawa1, Kouhei Ohno1, Yukishige 
Kimura1, Yuki Tatekoshi1, Kei Nakata1, Wataru Ohwada1, Masashi Mizuno1 & Tetsuji Miura1
Diabetes mellitus is a major risk factor for acute kidney injury (AKI). Here, we hypothesized that 
suppression of autophagic response underlies aggravation of renal ischemia/reperfusion (I/R) injury by 
type 2 diabetes mellitus (T2DM). In OLETF, a rat model of T2DM, and its non-diabetic control, LETO, AKI 
was induced by unilateral nephrectomy and 30-min occlusion and 24-h reperfusion of the renal artery 
in the contralateral kidney. Levels of serum creatinine and blood urea nitrogen and tubular injury score 
after I/R were significantly higher in OLETF than in LETO. Administration of chloroquine, a widely used 
autophagy inhibitor, aggravated I/R-induced renal injury in LETO, but not in OLETF. In contrast to LETO, 
OLETF exhibited no increase in autophagosomes in the proximal tubules after I/R. Immunoblotting 
showed that I/R activated the AMPK/ULK1 pathway in LETO but not in OLETF, and mTORC1 activation 
after I/R was enhanced in OLETF. Treatment of OLETF with rapamycin, an mTORC1 inhibitor, partially 
restored autophagic activation in response to I/R and significantly attenuated I/R-induced renal 
injury. Collectively, these findings indicate that suppressed autophagic activation in proximal tubules 
by impaired AMPK/ULK1 signaling and upregulated mTORC1 activation underlies T2DM-induced 
worsening of renal I/R injury.
Diabetes mellitus is a major risk factor for kidney damage. Diabetic nephropathy is a microvascular complication 
and is the most common cause of end-stage renal disease in many countries. In addition, patients with diabetes 
mellitus have increased risk for acute kidney injury (AKI), a condition of abrupt decline in kidney function by 
renal or extra-renal causes1, 2. Since the development of AKI is associated with poor prognosis in critically and 
non-critically sick patients3, 4, prevention of AKI in patients with AKI risk factors, including diabetes mellitus, is 
an important clinical issue. Studies using animal models of type 1 diabetes (T1DM) and type 2 diabetes (T2DM) 
have demonstrated that renal damage after ischemia/reperfusion (I/R), a main cause of AKI5, was enhanced 
by diabetes6–8. However, the mechanism by which diabetes increases susceptibility to AKI has not been fully 
elucidated.
Autophagy is a cellular process in which cytoplasmic components and damaged organelles are degraded in 
autolysosomes to recycle them as energy sources and to maintain protein quality and cellular homeostasis9–11. It 
has been reported that podocyte-specific deletion of Atg5, an essential autophagy gene, enhanced age-dependent 
glomerulosclerosis12. Deficiency of Atg5 in proximal tubules was shown to induce tubular degeneration13. These 
findings indicate crucial roles of autophagy in maintaining homeostasis of both the podocyte and the tubular cell. 
In addition to its house-keeping function, autophagy responds to various cellular stresses11. Podocyte-specific 
deletion of Atg5 promoted diabetes-induced glomerulopathy in murine models of T1DM14 and T2DM15, indicat-
ing that autophagy in the podocyte counteracts metabolic stress by diabetes. I/R activates autophagy in tubular 
cells13, 16–19, and inhibition of the autophagy by an inhibitor such as chloroquine (CQ) or 3-methyladenine17 or by 
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deletion of Atg513, 18 or Atg720 in proximal tubular cell aggravated renal damage after I/R in mice. Thus, autophagy 
activated by I/R appears to have a protective role against I/R-induced renal damage.
A few lines of evidence indicate that diabetes mellitus impairs autophagy21. We recently found that myocar-
dial autophagy in response to heart failure by acute myocardial infarction (AMI) was attenuated in a rat model 
of T2DM and that the impaired autophagic response was associated with increased mortality after AMI22. Basal 
autophagy in renal tubular cells was reported to be suppressed in Wistar fatty rats23. Autophagic activity in 
podocytes was found to be increased in mice with streptozotocin-induced diabetes before the development of 
glomerular lesions, but the activity decreased when mice exhibited glomerular lesions14, 24, 25. Diet-induced obe-
sity reportedly suppressed proteinuria-induced activation of autophagy in the proximal tubular cells of mice26. 
However, it remains unclear whether activation of autophagy in tubular cells in response to I/R is impaired by 
diabetes and whether such an impairment, if any, contributes to diabetes-induced increase in renal susceptibility 
to I/R injury. To address these issues, we examined differences in renal autophagy and I/R-induced AKI between 
Otsuka Long-Evans Tokushima Fatty rats (OLETF), a model of T2DM, and non-diabetic controls, Long-Evans 
Tokushima Otsuka rats (LETO). In addition, the relationship between autophagy and AKI in OLETF was exam-
ined by pharmacological manipulation of autophagic flux.
Results
Basal renal status in LETO and OLETF. OLETF at the age of 25–30 weeks were heavier than LETO and 
their levels of fasting blood glucose and glycoalbumin were significantly higher than those in age-matched control 
LETO (Table 1). Serum creatinine and blood urea nitrogen (BUN) levels were not increased in OLETF at this 
age compared with the levels in LETO (Table 1). However, consistent with previous reports27, 28, OLETF showed 
higher urine albumin/creatinine and urine protein/creatinine ratios and greater kidney weight than those in 
LETO (Table 1). In addition, periodic acid-Schiff (PAS) staining showed that the mesangial areas tended to be 
increased and that the glomerular areas were significantly enlarged in OLETF compared with those in LETO 
(Supplementary Fig. 1). These findings indicate that OLETF had developed overt nephropathy at this age.
Renal damage after ischemia/reperfusion in LETO and OLETF with and without autophagy 
inhibitor. We assessed renal damage after I/R in LETO and OLETF and also the effect of autophagy inhi-
bition on I/R-induced renal damage by using chloroquine (CQ, 10 mg/kg/day), a widely used inhibitor of 
autophagy17, 22, 29–31. LETO (n = 13), OLETF (n = 12), CQ-treated LETO (LETO+CQ, n = 9), and CQ-treated 
OLETF (OLETF+CQ, n = 10) underwent nephrectomy of the right kidney followed by 30-min ischemia/24 
h-reperfusion in the left kidney. We employed this one-kidney one-I/R model as in earlier studies32–34 because, 
in pilot experiments, bilateral renal I/R resulted in a large data variation between experiments in our hands (data 
not shown). The unilateral renal I/R method has an advantage that the right kidney removed before I/R of the 
contralateral kidney serves as control tissue before I/R. Mortality at 24 h after surgery was 0% in LETO, OLETF 
and CQ-treated OLETF, and one rat in the LETO+CQ group died of an unknown cause just after the surgery. 
One LETO was excluded from analyses because reperfusion was failed due to a technical problem.
Serum creatinine and BUN levels were 1.86 ± 0.35 mg/dl and 64.3 ± 6.0 mg/dl, respectively, in LETO 
after I/R (Fig. 1A and B). In OLETF, levels of serum creatinine (3.84 ± 0.25 mg/dl) and BUN (87.2 ± 4.1 mg/
dl) after I/R were significantly higher than those in LETO after I/R. CQ treatment in LETO also increased lev-
els of both serum creatinine (3.43 ± 0.39 mg/dl) and BUN (83.0 ± 5.9 mg/dl) after I/R compared with those of 
LETO (Fig. 1A and B). In contrast, pretreatment with CQ did not further increase levels of serum creatinine and 
BUN (4.34 ± 0.12 mg/dl, and 95.5 ± 3.4 mg/dl, respectively) in OLETF (Fig. 1A and B). Although tubular injury 
scores before I/R were comparable among the groups, the score after I/R was significantly higher in OLETF 
and LETO+CQ than in LETO (Fig. 1C and D). CQ did not significantly change tubular injury score in OLETF 
(Fig. 1C and D). Heart rate at 24 h after I/R under anesthesia was lower in OLETF than in LETO, and CQ treat-
ment decreased heart rate at 24 h after I/R in LETO, but not in OLETF (Supplementary Table 1). These findings 
indicate that diabetes aggravates I/R-induced renal injury and confirmed that autophagic activation in response to 
renal I/R is renoprotective as previously reported13, 17, 18, 20. In addition, absence of significant aggravation of renal 
injury by CQ in OLETF suggests that renoprotective autophagy is substantially suppressed in OLETF.
Impaired activation of autophagy in tubular cells in response to I/R in OLETF. We next examined 
whether autophagic activation in response to I/R is altered in OLETF. In immunofluorescence analysis for LC3, 
LC3 dots were detected in proximal tubular cells that were labeled by Lotus tetragonolobus lectin (LTL) conjugated 
LETO (N = 6) OLETF (N = 6)
Body weight (g) 505 ± 11 609 ± 12*
Blood glucose (mg/dl) 114 ± 5 240 ± 33*
Glycoalbumine (%) 10.6 ± 0.3 14.2 ± 3.5*
Serum creatinine (mg/dl) 0.61 ± 0.04 0.41 ± 0.02*
Blood urea nitrogen (mg/dl) 15.8 ± 1.0 13.9 ± 0.5
Urine albumin/creatinine ratio (g/g) 0.61 ± 0.23 1.79 ± 0.40*
Urine protein/creatinine ratio (g/g) 0.62 ± 0.20 6.36 ± 2.43*
Kidney weight (g) 1.23 ± 0.04 1.88 ± 0.07*
Table 1. Baseline parameters in LETO and OLETF. Values are means ± SEM. *p < 0.05 vs. LETO.
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with Texas Red (Fig. 2A). Before I/R, the number of LC3 dots tended to be larger in OLETF than in LETO. CQ 
pretreatment increased LC3 dots at baseline in LETO, indicating accumulation of autophagosomes by inhibited 
lysosome function. I/R significantly increased LC3 dots in LETO but not in OLETF (Fig. 2B). The I/R-induced 
increase in LC3 dots was enhanced in the LETO+CQ group (Fig. 2B).
Immunoblot analysis showed that LC3-II/LC3-I ratio, an index of LC3-I to LC3-II conversion, was rather 
decreased after I/R due to an increase in LC3-I level (Fig. 3A and C) in both LETO and OLETF. The level of 
LC3-II, an autophagosome marker, was not changed by I/R in LETO, and the LC3-II levels after I/R were similar 
in LETO and OLETF (Fig. 3A and C). These immunoblot results are apparently inconsistent with the results 
of immunofluorescence analyses (Fig. 2). The inconsistency may be due to the fact that whole kidney tissue 
lysates were used for immunoblotting. Nevertheless, LC3-II/LC3-I ratio after I/R was lower in OLETF than in 
LETO (Fig. 3A and C), suggesting attenuated autophagic response in OLETF. Protein levels of p62, a marker of 
autophagic activity35, were similarly increased after I/R in both LETO and OLETF (Fig. 3A and B). The protein 
level of beclin-1, a key regulator of autophagy as well as an autophagy marker in the kidney36, 37, was significantly 
upregulated after I/R in LETO but not in OLETF (Fig. 3D and E).
Alterations in signals that regulate autophagy in OLETF. AMP-activated protein kinase (AMPK) 
activates autophagy by phosphorylating ULK138, 39, and ischemia activates AMPK in cortical tubules40. To assess 
AMPK/ULK1 activity in the kidney tissue, immunoblotting was performed. Phospho-Thr172 AMPKα levels 
before ischemia were similar in LETO and OLETF. I/R significantly increased phospho-AMPKα levels in LETO 
but not in OLETF (Fig. 4A and B). The phosphorylation level of ULK1 at Ser555, one of the phosphorylation 
targets of AMPK for ULK1 activation38, was significantly increased by I/R in LETO but not in OLETF (Fig. 4C 
Figure 1. Type 2 diabetes and chloroquine increased susceptibility of the kidney to ischemia/reperfusion 
injury. Serum creatinine (A) and blood urea nitrogen (BUN) (B) levels of LETO (N = 12), OLETF (N = 12), 
LETO treated with chloroquine (LETO+CQ, N = 8), and OLETF treated with chloroquine (OLETF+CQ, 
N = 10) at 24 h after ischemia and reperfusion. (C) Representative images of hematoxylin-eosin staining of renal 
tissues at 24 h after ischemia/reperfusion. (D) Tubular injury score of renal tissues of before ischemia (Pre) and 
24 h after ischemia/reperfusion (I/R) in the four groups. *P < 0.05. Scale bar, 100 μm. NS = not significant.
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and D). SIRT1, an NAD+-dependent protein deacetylase, is reported to positively regulate AMPK activity via 
deacetylation of LKB1, an upstream AMPK activator41. In addition, SIRT1 is expressed in glomerular and prox-
imal tubular cells in the kidney, and SIRT1 in the tubular cells is reported to be markedly downregulated in a 
model of T1DM42. Therefore, we hypothesized that downregulation of SIRT1 contributes to impaired AMPK 
activation in OLETF. Immunoblotting showed that SIRT1 protein level in the kidney was significantly upregu-
lated after I/R in LETO, but not in OLETF (Fig. 4E and F). These findings suggest that impaired activation of the 
SIRT1/AMPK/ULK1 pathway contributed to impaired autophagic activation in OLETF.
We next examined whether mechanistic target of rapamycin complex 1 (mTORC1) signaling, a nega-
tive regulator of autophagy, is altered in OLETF. Basal levels of phospho-Thr389 p70S6 kinase (p70S6K) and 
phospho-Ser235/236 S6 were significantly lower in OLETF than in LETO, and I/R significantly increased 
the phosphorylation of p70S6K and S6 in both LETO and OLETF (Fig. 5A and B). Although levels of 
phospho-p70S6K and phospho-S6 after I/R were comparable in LETO and OLETF, the degree of change by I/R in 
phospho-S6 level was greater in OLETF (Fig. 5B, right panel). Total p70S6K protein level was also increased after 
I/R in both groups (Fig. 5A).
Phospho-Ser473 level of Akt, an upstream regulator of mTORC1, was significantly reduced in OLETF com-
pared with that in LETO. However, I/R increased phospho-Akt levels in both groups, and there was no significant 
difference between phospho-Akt levels after I/R in LETO and OLETF (Fig. 5C and D).
Figure 2. Autophagic response in proximal tubular cells after ischemia/reperfusion was attenuated in 
OLETF. (A) Representative immunofluorescence images of LC3 (green) and the proximal tubular marker 
lotus tetragonolobus lectin conjugated with Texas Red (LTL; red) in the kidneys of LETO, OLETF, and LETO 
treated with chloroquine (LETO+CQ). Nuclei were stained with Hoechst33342. Pre: pre-ischemia, I/R: 24 h 
after ischemia/reperfusion. (B) Summary data of LC3 dot numbers. N = 4 in each group. *P < 0.05, NS = not 
significant. Scale bar, 50 μm.
www.nature.com/scientificreports/
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Immunohistochemistry revealed that phospho-S6 was present mainly in tubular cells and parietal epithelial 
cells in OLETF before ischemia (Fig. 5E). As observed in immunoblotting, phospho-S6 staining was also reduced 
in OLETF before I/R, especially in proximal tubular cells. I/R increased phospho-S6-positive tubular cells in 
LETO and OLETF (Fig. 5E).
Restoration of autophagy by rapamycin attenuated I/R-induced renal injury in OLETF. Finally, 
we examined whether restoration of renal autophagy attenuates I/R-induced renal damage in OLETF. To acti-
vate autophagy, we chose an mTORC1 inhibitor rapamycin. OLETF were assigned to a vehicle group (n = 7) 
and a rapamycin group (n = 7). All of the rats were alive at 24 h after I/R. Rapamycin did not affect levels of 
blood glucose, glycoalbumin, total cholesterol, and triglyceride after I/R (Supplementary Table 2). Heart rate and 
blood pressure at 24 h after I/R were not changed by rapamycin treatment (Supplementary Table 3). Rapamycin 
modestly, but significantly decreased serum creatinine level after I/R to 3.08 ± 0.50 mg/dl compared with that in 
vehicle-treated animals (4.40 ± 0.21 mg/dl), though BUN level was unchanged (Fig. 6A and B). Tubular injury 
score after I/R was also significantly lower in rapamycin-treated OLETF than in vehicle-treated animals (Fig. 6C 
and D). Rapamycin completely suppressed elevation of phospho-p70S6K and phospho-S6 levels induced by I/R 
(Fig. 7A and B). Immunofluorescent labeling of LC3 revealed that rapamycin partially, but significantly, restored 
I/R-induced increase of autophagosomes in tubular cells in OLETF (Fig. 7C and D). Rapamycin significantly 
reduced p62 protein level after I/R (Fig. 7E and F) and increased LC3-II/LC3-I ratio and LC3-II level at baseline 
and after I/R (Fig. 7E and G).
Figure 3. Activation of renal autophagy after ischemia/reperfusion was reduced in OLETF. (A) Representative 
immunoblot images for p62 and LC3 in the kidney. Summary data for p62 (B) and LC3-II/LC3-I ratio, LC3-II, 
and LC3-I (C) in total kidney tissues before ischemia (Pre) and 24 h after ischemia/reperfusion (I/R). Ratio of 
LC3-II to LC3-I after I/R was significantly reduced in OLETF. Representative immunoblots for beclin-1 (D) and 
summary data (E) in kidney tissues. Beclin-1 protein level was increased after I/R only in LETO. N = 8 in each 
group. *P < 0.05, NS = not significant.
www.nature.com/scientificreports/
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Discussion
In the present study, OLETF showed higher serum creatinine and BUN levels and higher tubular injury score 
after renal I/R than those in LETO. Such augmented AKI in OLETF was associated with significant suppression 
of the I/R-induced increase in autophagosomes in tubular cells and reduction in the LC3-II/LC3-I ratio. The 
augmentation of renal I/R injury in OLETF was mimicked in LETO treated with CQ, an inhibitor of autophagy, 
whereas CQ did not further increase I/R injury in OLETF. Conversely, rapamycin, a promoter of autophagy, sig-
nificantly restored I/R-induced autophagic response and reduced both serum creatinine level and tubular injury 
score after renal I/R in OLETF. These findings support the hypothesis that impaired autophagic response in tubu-
lar cells underlies the aggravation of renal I/R injury by T2DM. This is the first study indicating the involvement 
of impaired autophagy in T2DM-induced aggravation of AKI.
We used OLETF at ages of 25–30 weeks when early stage of diabetic nephropathy had been developed 
(Table 1). Since multiple mechanisms are involved in diabetic nephropathy, there is the possibility that both 
autophagy-dependent and –independent mechanisms of renoprotection are impaired in OLETF with diabetic 
nephropathy. However, administration of CQ, an autophagy inhibitor, to LETO reproduced change in serum 
levels of creatinine and BUN and tubular injury score after I/R in OLETF (Fig. 1). On the other hand, CQ did 
not further augment I/R injury in OLETF, arguing against the possibility that the effect of CQ in LETO was 
due to toxicity unrelated to autophagy inhibition. Thus, autophagy-independent factors associated with diabetic 
nephropathy, if any, are unlikely to play a major role in increased renal susceptibility to I/R in OLETF.
As in earlier studies13, 16–19, I/R induced a significant increase in autophagosomes labelled by fluorescent LC3 
in renal tubular cells in non-diabetic controls, LETO (Fig. 2). The increase in autophagosomes is explained by 
promotion of autophagosome formation, not by suppression of autophagosome clearance, because inhibition of 
Figure 4. Analysis of AMPK/ULK1 signal pathways. (A) Representative immunoblots for phospho-Thr172 
and total AMPKα in renal tissues before ischemia and 24 h after reperfusion in LETO and OLETF. Pre: 
pre-ischemia, I/R: 24 h after ischemia/reperfusion. (B) Summary data for phospho-Thr172 AMPKα level 
normalized by β-actin. Phospho-AMPKα level was significantly increased after I/R in LETO but not in OLETF. 
(C) Representative blots for phospho-Ser555 and total ULK1. The blot of β-actin is identical to that in Fig. 3D 
because blots of both beclin-1 and ULK1 were from the same membrane. (D) Summary data for phospho-
ULK1 level normalized by total ULK1. Phospho-ULK1 level was also elevated after I/R only in LETO. N = 8 
in each group. (E) Representative blots for SIRT1 in renal tissues. (F) Summary data for SIRT1 protein level 
normalized by β-actin. In contrast to LETO, I/R failed to increase SIRT1 protein level in OLETF. N = 6 in each 
group. *P < 0.05. NS = not significant.
www.nature.com/scientificreports/
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autophagic flux by CQ further increased autophagosomes in the tubules after I/R (Fig. 2). In contrast to LETO, 
OLETF showed no significant increase in autophagosomes in renal tubular cells after I/R, indicating impaired 
activation of autophagy in response to I/R. This notion is consistent with lack of beclin-1 upregulation after I/R 
in OLETF (Fig. 3D and E).
The mechanism of I/R-induced activation of autophagy in the kidney has not been fully evaluated. Renal 
ischemia was reported to induce AMPK phosphorylation globally including tubular cells in rodents40, 43. 
Consistent with the earlier reports, we found that I/R significantly increased phosphorylation levels of both 
AMPKα and ULK1 in LETO (Fig. 4). Interestingly, mTORC1, which suppresses autophagy, was also activated 
after I/R (Fig. 5). Therefore, it is likely that AMPK-ULK1 is mainly responsible for I/R-induced activation of 
autophagy in renal tubular cells in LETO. However, such I/R-induced phosphorylation of AMPK and ULK1 was 
not observed in OLETF (Fig. 4). In addition, the increase in phospho-S6 level by I/R was significantly greater in 
OLETF than in LETO (Fig. 5). Since AMPK is known to suppress mTORC1 activity by phosphorylating tuberous 
sclerosis complex44, attenuated AMPK activation in OLETF may have led to hyperactivation of mTORC1. Taken 
together, these findings suggest that blunted autophagic response to I/R in OLETF is attributable to suppressed 
activity of AMPK/ULK1 and enhanced mTORC1 activation.
Attenuation of AMPK activation in the kidney of OLETF (Fig. 4) is consistent with findings in other animal 
models of diabetes mellitus45, 46, and the effect of diabetes mellitus on AMPK does not appear to be kidney-specific 
since we recently found that activation of myocardial AMPK in response to acute heart failure was impaired by 
T2DM22. How T2DM suppresses AMPK activity remains unclear. However, there are a few possible explanations. 
In the present study, SIRT1, a protein deacetylase, which activates AMPK activation41, was upregulated after I/R 
Figure 5. Analysis of Akt/mTORC1 signal pathways. Representative immunoblots (A) and summary data 
(B) for phospho-Thr389 and total p70S6 kinase (p70S6K), phospho-Ser235/236 and total S6, and actin in 
renal tissues before ischemia and 24 h after reperfusion in LETO and OLETF. Pre: pre-ischemia, I/R: 24 h after 
ischemia/reperfusion. (B) Before ischemia, phospho-p70S6K and phospho-S6 levels were reduced in OLETF. 
Levels of phospho-p70S6K and phospho-S6 were increased after I/R in both groups. The change in phospho-S6 
level (ΔP-S6/T-S6) from the pre-ischemic period to 24 h after I/R was greater in OLETF than in LETO. (C) 
Representative immunoblots for phospho-Ser473 and total Akt. (D) Phospho-Akt level before ischemia was 
lower in OLETF than in LETO. I/R increased phospho-Akt levels in both OLETF and LETO, and phospho-
Akt levels after I/R were similar in LETO and OLETF. N = 8 in each group. (E) Representative images of 
immunostaining for phospho-S6 in kidney sections before and 24 h after ischemia/reperfusion in LETO and 
OLETF. Scale bar, 100 μm. *P < 0.05.
www.nature.com/scientificreports/
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in LETO but not in OLETF (Fig. 4). The suppressed expression of SIRT1 is a possible mechanism of impaired 
AMPK activation in OLETF. In addition, attenuation of upstream AMPK kinase activity, enhanced activity of 
AMPK phosphatase, or an increase in inhibitory phosphorylation on AMPK at Ser485/491 are also possible 
mechanisms of the suppression of AMPK activity. However, since AMPK-Ser485 is a target site of Akt47, compa-
rable phosphorylation levels of Akt-Ser473 in OLETF and LETO after I/R (Fig. 5) argue against the involvement 
of this regulation in T2DM-induced suppression of AMPK.
mTORC1 activity in the kidney was significantly increased after I/R (Fig. 5A and B), which is consistent 
with the previous reports19, 32, 48, 49. To induce renal I/R injury, we employed combination of right nephrectomy 
and 30-min ischemia/24 h-reperfusion in the left kidney. It was reported that unilateral nephrectomy itself led 
to mTORC1 activation in the contralateral kidney as a hypertrophic signaling even 24 h after surgery in mice50 
and such an impact of unilateral nephrectomy in diabetic animals remains unclear. However, using the same 
one-kidney one-I/R model, Lieberthal et al.32 showed that phospho-p70S6K level was markedly higher in the 
kidney after I/R than that in the sham-operated remaining kidney after unilateral nephrectomy. In addition, 
significant activation of mTORC1 occurred in the post-ischemic kidney compared with sham in mouse models 
without nephrectomy19, 49. The findings suggest that I/R rather than nephrectomy largely accounts for mTORC1 
activation observed in the kidney subjected to I/R in the present study.
The present study provided evidence indicating that impaired autophagy contributes to enhancement of renal 
I/R injury by diabetes mellitus and also showed that restoration of autophagy in the diabetic kidney is achievable 
Figure 6. Effects of rapamycin on kidney injury after ischemia/reperfusion in OLETF. Levels of serum 
creatinine (A) and blood urea nitrogen (BUN) (B) 24 h after renal ischemia/reperfusion in OLETF treated with 
a vehicle (N = 7) or rapamycin (Rapa, 0.25 mg/kg, N = 7) 30 min prior to ischemia in OLETF. (C) Representative 
images of hematoxylin-eosin staining of renal tissues at 24 h after ischemia/reperfusion. (D) Tubular injury 
score before ischemia and 24 h after reperfusion in OLETF treated with vehicle or rapamycin. Pre: pre-ischemia, 
I/R: 24 h after ischemia/reperfusion. *P < 0.05. Scale bar, 100 μm.
www.nature.com/scientificreports/
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Figure 7. Restoration of autophagic response by rapamycin in OLETF. (A) Representative images of 
immunoblotting for phospho-Thr389 and total p70S6 kinase (p70S6K) and for phospho-Ser235/236 and total 
S6 of kidney tissues before ischemia and 24 h after reperfusion in OLETF pretreated with a vehicle (N = 7) or 
rapamycin (N = 7). Pre: pre-ischemia, I/R: 24 h after ischemia/reperfusion, Rapa; rapamycin-treated group. (B) 
I/R-induced increases in phospho-p70S6K and phospho-S6 levels were completely suppressed by rapamycin. 
(C) Representative immunofluorescence images of LC3 (green) and the proximal tubular marker lotus 
tetragonolobus lectin conjugated with Texas Red (LTL; red) in the kidneys from OLETF administered a vehicle 
or rapamycin. Nuclei were stained with Hoechst33342. (D) Summary data for LC3 dot level. (E) Representative 
blots for p62 and LC3. (F) Protein level of p62 after I/R was significantly reduced by rapamycin in OLETF. (G) 
LC3-II/LC3-I ratio after I/R was significantly increased by rapamycin, and the change was associated with a 
significant increase in LC3-II protein level. Scale bar, 50 μm. *P < 0.05.
www.nature.com/scientificreports/
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by the use of rapamycin (0.25 mg/kg) (Fig. 7D). It is notable, however, that the renoprotective effect of rapamy-
cin was relatively small while rapamycin almost completely suppressed mTORC1 activity. The relatively small 
impact of rapamycin on I/R injury might be due to incomplete restoration of autophagy. Not only modification of 
mTORC but also impaired AMPK activation are suggested to be responsible for suppressed autophagy in OLETF, 
and it is possible that AMPK activation needs to be restored for full activation of autophagy in OLETF. Selection 
of a dose of rapamycin for restoring autophagy in the kidney is actually difficult, and high doses of rapamycin can 
be detrimental to renal functions. In a study by Li et al.19, rapamycin treatment (5 mg/kg 1 day before and 2 days 
after I/R) reduced Ki67-positive injured proximal tubular cells after renal I/R in mice, and Grahammer et al.51 
reported that inhibition of mTORC1 by deletion of raptor rather enhanced renal tubular injury and prevented 
proliferative response after I/R. In fact, in our pilot experiments, a high dose of rapamycin (2 mg/kg) administered 
prior to I/R did not afford significant renal protection in OLETF (data not shown). Strategy for restoring renopro-
tective autophagy warrants further investigation.
In the present study, rapamycin reduced tubular injury and serum creatinine level but not BUN level 24 h after 
I/R in OLETF. One possible explanation for the lack of significant change in BUN is that protection by rapamycin 
was not strong enough to decrease BUN level probably due to incomplete restoration of autophagic activation and 
suppression of the renal repair process afforded by mTORC1 as described above51. Another explanation is differ-
ent time courses of BUN and creatinine level after I/R. Previous studies showed that serum BUN level reached the 
peak between 24 and 72 h following reperfusion while serum creatinine level peaked at 24 h after reperfusion52, 53. 
Therefore, it is possible that reduction of BUN level by rapamycin in OLETF could have been detected at 48~72 h 
after reperfusion.
p53 has been reported to be involved in I/R-induced AKI and cisplatin-induced AKI54, 55. Furthermore, a 
recent study by Peng et al.8 indicated that upregulation of p53 underlies the diabetes-induced enhancement of 
AKI. Using two models of T1DM, they showed that p53 protein level in the kidney was more upregulated after I/R 
in diabetic mice than in non-diabetic control mice. Interestingly, inhibition of p53 by pifithrin-α or knockdown 
of p53 by siRNA attenuated renal I/R injury assessed by serum creatinine level and histological tubular injury in 
diabetic mice8. However, we did not observe significant increase in p53 protein after I/R in the kidney of LETO 
or OLETF (Supplementary Fig. 2). Thus, the role of p53 in renal I/R injury might be different between T1DM and 
T2DM or between different protocols of I/R.
It remains unclear how autophagy exerts protection against I/R-induced renal injury. However, circumstantial 
evidence suggests that preservation of mitochondrial function is involved in the protection. Autophagy is impor-
tant for re-cycling cellular components, including amino acids and lipids, and for elimination of damaged intra-
cellular organelles, including mitochondria. Proximal tubular cells are rich in mitochondria and their function 
greatly depends on oxidative phosphorylation. A proximal tubule-specific defect of autophagy by Atg5 knockout 
has been shown to cause accumulation of deformed and damaged mitochondria13, 18. Furthermore, Kimura et al.56 
showed that deletion of Atg5 significantly exaggerated metabolic stress on tricarboxylic acid cycle by cyclosporine 
A, leading to ATP depletion and enhanced production of reactive oxygen species (ROS), in proximal tubular 
cells. I/R not only reduces ATP-producing capacity of mitochondria but also increases ROS production57. Thus, 
preservation of energy substrates and mitochondrial function and elimination of cytotoxic ROS produced from 
damaged mitochondria are plausible mechanisms for renal protection afforded by autophagy. The contribution of 
such mechanisms needs to be examined by further investigations.
Although p62 protein level is often used as a marker of autophagic activity35, its level in whole kidney lysates 
was not useful for assessment of autophagic activity in the present study. The level of p62 was markedly increased 
after I/R in both LETO and OLETF without an inter-group difference (Fig. 3), though a difference in auto-
phagic flux after I/R between the groups was indicated by analyses of LC3-positive autophagosomes (Fig. 2). 
Additionally, CQ did not change p62 protein level before and after I/R (data not shown). Consistent with the 
present results, earlier studies have shown that p62 protein increased in the kidney after I/R49, 58 and during 
cisplatin-induced acute injury20. Decleves et al.58 speculated that activity of autophagy during I/R was insufficient 
to clear p62 protein because p62 upregulation was suppressed by further promotion of autophagy by activating 
AMPK. In fact, promotion of autophagy by rapamycin reduced the level of p62 (Fig. 7E). However, changes in p62 
level in OLETF cannot be explained by autophagy activity alone, because p62 protein level after I/R in OLETF, 
in which autophagic response was blunted, was similar to that in LETO (Fig. 3A and B). Another possible expla-
nation for I/R-induced p62 upregulation is transcriptional activation of p62 by I/R-induced activation of Nrf2, a 
transcription factor targeting p62, in the kidney59, 60.
As a model of T2DM in the present study, we selected OLETF that is hyperphagic due to lack of functional 
cholecystokinin (CCK)-1 receptor. Zucker diabetic fatty (ZDF) rats, a model with defective leptin signaling, is 
also widely used, and suppressed activities of autophagy in the brain and myocardium have been shown in this 
model61, 62. However, since leptin reportedly modulates autophagy63–65, contribution of defective leptin signaling 
per se to modification of autophagy cannot be excluded in ZDF. Importantly, impaired autophagic activity has 
been reported for human samples; kidney biopsy samples26 and endothelial cells66 from diabetic patients showed 
reduced autophagic activity. Therefore, impaired autophagy is likely to be a common feature in T2DM regardless 
of genetic background or etiology.
In conclusion, T2DM impairs autophagic response to I/R in the kidney via suppression of SIRT1/AMPK/
ULK1 signaling and enhancement of mTORC1, and the insufficient activation of autophagy during I/R contrib-
utes to aggravation of I/R-induced AKI by T2DM.
Methods
Animals and experimental protocol. The present study was conducted in strict accordance with the 
Guide for the Care and Use of Laboratory Animals published by National Research Council of the National 
Academies, USA (2011) and was approved by the Animal Use Committee of Sapporo Medical University. Male 
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LETO and OLETF at ages of 25–30 weeks were used in all experiments. In a group of CQ-treated LETO and a 
group of CQ-treated OLETF, CQ (10 mg/kg/day, Sigma-Aldrich, St. Louis, MO, USA) was administered subcuta-
neously by osmotic minipumps (Alzet, Cupertino, CA, USA) for 1 week. The dose of CQ was selected on the basis 
of results in earlier reports22, 29, 30. Using separate groups of OLETF, we tested the effect of restoring autophagy 
by inhibition of mTORC1 on renal injury. Either rapamycin (0.25 mg/kg, LC laboratories, Woburn, MA) or its 
vehicle (0.25% Tween 80, 0.25% polyethylene glycol) was administered to OLTEF intraperitoneally 30 min before 
induction of renal I/R.
Assessment of basal renal status in LETO and OLETF. To assess basal renal status, blood, urine, and 
kidney tissues were sampled from LETO and OLETF after fasting for 12 h. Rats were anesthetized with 2.5% iso-
flurane inhalation and supplemental oxygen, and blood was collected via a catheter cannulated into the carotid 
artery. After opening the abdominal cavity, the kidneys were removed, quickly weighed, washed in ice-cold saline, 
and then stored for histological analyses. Area of glomerular and mesangial matrix was determined in PAS stain-
ing by using Nikon NIS-elements software (Nikon, Japan). Mesangial area was selectively highlighted by using 
a threshold tool of NIS Elements, and this threshold was applied for all samples. Urine was aspirated from the 
urinary bladder.
Induction of I/R in the kidney. Animals were fasted 12 h before the experiment. Rats were anesthetized 
with isoflurane as described above and placed on a heating pad to maintain rectal temperature at 37 °C. In a prone 
position, surgery was performed using a dorsal approach. The right kidney was gently pushed out of the body 
cavity and then removed. The removed right kidney was immediately placed in ice-cold saline and cut in halves. 
One of the halves was stored at −80 °C and the other was fixed in 10% formaldehyde. Next, the left kidney was 
exposed and its renal pedicle was occluded using a vascular clamp for 30 min to induce ischemia. The ischemic 
kidney was placed within the body cavity to avoid the effect of hypothermia on renal damage. After reperfusion 
by releasing the clamp, the muscle layers of the incision and skin wound were closed. After surgery, the animals 
were allowed to feed and drink water ad libitum. Sterilized instruments were used for the surgical preparation.
Blood and kidney tissue sampling after renal I/R. At 24 h after reperfusion, rats were re-anesthetized 
with isoflurane. Blood pressure and heart rate were monitored, and blood samples were taken via a catheter 
placed in the carotid artery. The abdomen was opened, and the kidney was excised and immediately immersed 
in iced-cold saline. The kidney was halved for storing one half at −80 °C and for fixing the other half with 10% 
formaldehyde.
Assessment of renal injury. Renal injury was assessed histologically with hematoxylin and eosin staining 
and with PAS staining. Pictures of kidney tubular cells in the corticomedullary area were randomly taken and 
were scored as previously reported13. In brief, for each of four types of damages in tubules (i.e., loss of brush 
border, tubular dilation, cast formation, and cell lysis), a score was given according to the percentage of damaged 
areas (i.e., 1, <25% damaged; 2, 25–50% damaged; 3, 50–75% damaged; and 4, more than 75% damaged), and 
scores of the four types of damages were summed as a score for each area of interest. The score in each kidney was 
calculated as the average of scores of fifteen areas under magnification of x200 in light microscopy. In each group, 
7~10 kidneys were included for analysis.
Immunofluorescence. Frozen sections of renal tissues were fixed with 4% paraformaldehyde, blocked with 
5% bovine serum albumin in PBS, and permeabilized with 0.3% triton X-100. The sections were then incubated 
with anti-LC3A/B (Cell Signaling Technology, #12741, 1:50) overnight at 4 °C. The samples were then incubated 
with an Alexa Fluor 488 anti-rabbit IgG antibody (Invitrogen) for 1 h at room temperature. Nuclei and proximal 
tubular cells were stained with Hoechst33342 (Dojindo, Kumamoto, Japan) and LTL conjugated with Texas Red® 
(EY Laboratories, Inc., San Mateo, CA), respectively. We simultaneously conducted immunostaining for LC3 
in one kidney section per rat from LETO-pre (i.e., right kidney removed before left kidney I/R), LETO-I/R (left 
kidney subjected to I/R), OLETF-pre, OLETF-I/R, LETO+CQ-pre and LETO+CQ-I/R groups. Sections from a 
kidney from each of the six treatment groups were taken at the same session of confocal imaging under the same 
settings. Five fields in each section were randomly selected, and LC3 positive areas per field were averaged. Then, 
ratio of average LC3 dot level (LC3 positive area) to average LC dot level in LETO-Pre was calculated for each 
kidney as “relative LC3 dot number”. Finally, the “relative LC3 dot numbers” in 4~5 independent kidneys from 
each group were averaged. Fluorescence images were obtained using ConfoCor3LSM510META (Zeiss) under 
the same conditions. The percentage of area of LC3 dots was analyzed in five randomly selected fields in the each 
kidney, and 4~5 kidneys in each group were included for comparison among groups.
Immunoblotting. Frozen tissue samples were homogenized in ice-cold buffer (CelLytic™ MT Cell Lysis 
Reagent, Sigma-Aldrich) including protease and phosphatase inhibitor cocktails (Nacalai Tesque, Inc., Kyoto, 
Japan). The homogenate was centrifuged at 15,000 g for 15 min at 4 °C to obtain the supernatant. Equal amounts 
of protein were analyzed by immunoblot assays using specific antibodies (Supplementary Table 4). Intensities of 
individual bands were quantified by using Image J software (National Institutes of Health).
Statistical analyses. Data are presented as means ± SEM. Statistical significance was determined using 
unpaired Student’s two-tailed t-test for two data sets. Differences between four treatment groups were assessed 
by one-way analysis of variance (ANOVA) followed by the Student-Newman-Keuls post hoc test for multiple 
comparisons. Two-way repeated measures ANOVA and Student-Newman-Keuls post hoc test were used to ana-
lyze differences in data between pre-I/R and after I/R in LETO and OLETF. For all tests, p < 0.05 was considered 
statistically significant. All analyses were performed with SigmaStat (Systat, San Jose, CA, USA).
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Supplementary Table 1.  Hemodynamic parameters 24 h after renal ischemia/reperfusion                                                           
                                 LETO OLETF LETO+CQ OLETF+CQ 
                                 (N=12) (N=12) (N=8) (N=10) 
Heart rate (bpm) 349±4 277±12* 307±10* 260±9# 
Systolic blood pressure (mmHg) 104±3 104±2 108±3 117±3#† 
Diastolic blood pressure (mmHg) 72±4 70±3 66±2 79±2#† 
    






Supplementary Table 2.  Effect of rapamycin on metabolic parameters after renal 
ischemia/reperfusion.  





Body weight (g) 641±12 650±16 
  
Blood glucose (mg/dl) 231±21 234±20 
  
Glycoalbumin (%) 17.2±3.0 14.0±1.3 
  
Total cholesterol (mg/dl) 144±9 155±15 
  
Triglyceride (mg/dl) 147.6±48.5 148.0±33.0 
  






Supplementary Table 3.  Effects of rapamycin on hemodynamic parameters after 
renal ischemia/reperfusion  
OLETF+ Vehicle OLEFT+ Rapamycin 
 
  (N=7) (N=7) 
 
Heart rate (bpm) 306±14 285±10 
 
Systolic blood pressure (mmHg) 122±4 121±3 
 
Diastolic blood pressure (mmHg) 85±7 78±3 
 






Supplementary Table 4.  Antibodies used in the present study 
 
Antibodies Source Cat. No. dilution 
Guinea pig anti-polyclonal p62 Progen GP62-C 1:1000 
Rabbit monoclonal anti-LC3A/B Cell Signaling #12741 1:1000 
Rabbit polyclonal anti-phospho-Thr389-p70S6K Cell Signaling #9205 1:1000 
Rabbit polyclonal anti-p70S6K Cell Signaling #9202 1:1000 
Rabbit polyclonal anti-phospho-Ser235/236-S6 Cell Signaling #2211 1:1000 
Rabbit polyclonal anti-S6 Cell Signaling #2217 1:1000 
Rabbit polyclonal anti-phospho-Ser473-Akt Cell Signaling #9271 1:1000 
Rabbit polyclonal anti-Akt Cell Signaling #9272 1:1000 
Rabbit monoclonal anti-phospho-Thr172 
AMPK 
Cell Signaling #2535 1:1000 
Rabbit polyclonal anti-AMPK Cell Signaling #2532 1:1000 
Rabbit monoclonal anti-phospho-Ser555-ULK1 Cell Signaling #5869 1:1000 
Rabbit monoclonal anti-ULK1 Abcam ab128859 1:1000 
Rabbit monoclonal anti-Beclin-1 Cell Signaling #3495 1:1000 
Mouse monoclonal anti-p53 (1C12) Cell Signaling #2524 1:1000 
Mouse monoclonal anti-SIRT1 (19A7AB4) Abcam ab110304 1:2000 
Mouse monoclonal anti-β-actin Sigma-Aldrich A5316 1:10000 



























Supplementary Figure 1.  Sizes of glomerular areas and mesangial areas in LETO and OLETF.  
Representative glomeruli stained with PAS (A) and group mean data for glomerular area size (B) and 
for mesangial area size (C).  Fifteen glomeruli were randomly selected in each kidney sample and 
sizes of glomerular and mesangial areas were determined by Nikon NIS-elements software.  N = 5 in 















Supplementary Figure 2. Protein levels of p53 in LETO and OLETF before and after renal 
ischemia/reperfusion.Left panel: Representative immunoblots for p53 before ischemia (Pre) and 24 
h after ischemia/reperfusion (I/R). Right panel: group mean data for p53 protein level normalized by 
β-actin level (n = 8 in each treatment group). 
 
 
